Share This Page
Drugs in ATC Class N02BF
✉ Email this page to a colleague
Drugs in ATC Class: N02BF - Gabapentinoids
| Tradename | Generic Name |
|---|---|
| GABAPENTIN | gabapentin |
| GRALISE | gabapentin |
| HORIZANT | gabapentin enacarbil |
| LYRICA | pregabalin |
| NEURONTIN | gabapentin |
| PREGABALIN | pregabalin |
| >Tradename | >Generic Name |
N02BF Market Analysis and Financial Projection
The gabapentinoid market (ATC Class N02BF) has undergone significant transformation due to shifting therapeutic applications, patent expirations, and evolving regulatory landscapes. This analysis examines the forces shaping this pharmaceutical sector, focusing on gabapentin and pregabalin – two key drugs reclassified in 2023 under the new gabapentinoid category[3][16].
Market Overview
The global gabapentin market reached USD 2.3 billion in 2024, projected to grow at 4.92% CAGR through 2033[1]. Parallel data suggests even stronger growth potential, with some forecasts predicting USD 5.23 billion by 2034 as neuropathic pain management becomes a global health priority[14].
Key Growth Drivers:
- Rising neuropathic pain cases from diabetes (+30% global prevalence since 2015)[1]
- Off-label use expansion for anxiety and fibromyalgia (35% of prescriptions)[5]
- Cost advantage over opioids (generic gabapentin costs 80% less than branded versions)[10]
- Patent expirations enabling 46 generic manufacturers to enter the market[2]
Patent Landscape & Generic Competition
Neurontin® (Pfizer):
- Final patent expired November 2022 (US7256216)[2]
- 46 ANDA filers including Strides Pharma (600/800 mg approval March 2024)[1][10]
Gralise® (Depomed):
- Multiple patent challenges resolved through 2015-2024 litigation[6]
- Key patents US6723340 (expired) and US6340475 (expired)[6]
Market Impact:
- Generic penetration reached 68% in North America by 2024[14]
- ANDA filings accelerated through Paragraph IV certifications:
"Generic manufacturers can challenge patents through Paragraph IV certifications, forcing patent holders to litigate or negotiate early entry"[13]
Regulatory & Therapeutic Shifts
The 2023 WHO ATC reclassification reflects changing clinical priorities:
| Parameter | Pre-2023 | Post-2023 |
|---|---|---|
| Primary Indication | Epilepsy | Neuropathic Pain[3] |
| ATC Class | N03AX (Antiepileptics) | N02BF (Gabapentinoids)[16] |
| Therapeutic Focus | 40% seizure control | 82% pain management[8] |
This reclassification aligns with prescription patterns showing 18.7% of workers' compensation claimants receiving gabapentinoids in 2017 versus 7.9% in 2010[8].
Regional Dynamics
North America:
- Dominant market (37% share) with 6.58% CAGR through 2034[14]
- Regulatory focus on curbing off-label use (25% reduction in questionable prescriptions since 2022)[10]
Asia-Pacific:
- Fastest-growing region (8.1% CAGR) driven by:
- 150M+ diabetic patients in India[10]
- 45% cost advantage in API production[10]
- India exports 60% of generic gabapentin to US/UK markets[10]
Competitive Landscape
Brand Strategies:
- Lifecycle management through extended-release formulations (Gralise® Horizant®)[7]
- Pediatric dosage patents (US6054482 – expired 2017)[2]
Generic Dominance:
- Top 5 manufacturers control 58% market share[10]
- API sourcing from China/India (72% global production)[10]
Future Outlook
Emerging Trends:
- Combination therapies with NSAIDs (+23% R&D investment since 2022)[5]
- Digital therapeutics integration for dose optimization[14]
- Patent analytics driving generic entry strategies[9][12]
Key Challenges:
- Diversion risks (12% increase in non-medical use 2020-2024)[14]
- Regulatory harmonization across markets[10]
| Market Projections: | Metric | 2025 | 2033 | CAGR |
|---|---|---|---|---|
| Market Size | $3.07B[14] | $5.23B[14] | 6.07% | |
| Generic Penetration | 72% | 89% | +2.4% annually | |
| Asia-Pacific Growth | 28% | 37% | 8.1% |
"The gabapentinoid market represents a microcosm of modern pharma dynamics – expired patents creating generic opportunities while evolving therapeutic applications drive renewed growth" [10][14]
Key Takeaways:
- Neuropathic pain management drives 82% of current gabapentinoid use
- Generic competition intensifies with 46 ANDA filers active
- Asia-Pacific emerges as production hub and growth frontier
- Regulatory changes reshape prescription patterns and R&D focus
FAQs:
Q: When did major gabapentin patents expire?
A: Neurontin's final US patent expired Nov 2022[2], Gralise's key patents ended 2015-2022[6]
Q: Which region leads in generic exports?
A: India supplies 60% of US/UK generic gabapentin[10]
Q: How did ATC reclassification impact the market?
A: Increased focus on pain management (from 40% to 82% prescriptions)[3][8]
Q: What's driving Asia-Pacific growth?
A: Aging population (400M+ over 65 by 2030) and diabetes epidemic[10][14]
Q: Are new gabapentinoids in development?
A: Mirogabalin (N02BF03) entered markets in 2024 with enhanced bioavailability[16]
References
- https://www.imarcgroup.com/gabapentin-market
- https://pharsight.greyb.com/drug/neurontin-patent-expiration
- https://janusinfo.se/nyheter/nyheter/2023/nyatckodforgabapentinochpregabalin.5.636fcf0c186707f25a284ba9.html
- https://atcddd.fhi.no/atc_ddd_index/?code=N02BF01
- https://www.futuremarketinsights.com/reports/gabapentin-market
- https://pharsight.greyb.com/drug/gralise-patent-expiration
- https://www.kegg.jp/entry/D09539
- https://oem.bmj.com/content/81/5/245
- https://www.lexisnexisip.com/resources/patent-landscape-analysis/
- https://www.stellarmr.com/report/Gabapentin-Market/2072
- https://www.drugpatentwatch.com/p/generic-api/PREGABALIN
- https://www.ipcheckups.com/patent-landscape-analysis-overview/
- https://www.ftc.gov/sites/default/files/documents/reports/generic-drug-entry-prior-patent-expiration-ftc-study/genericdrugstudy_0.pdf
- https://www.precedenceresearch.com/gabapentin-market
- https://pharsight.greyb.com/collections/drugs-opening-to-patent-challenges-in-2025
- https://atcddd.fhi.no/atc_ddd_index/?code=N02BF&showdescription=no
- https://www.drugpatentwatch.com/p/atc-class/N02BF
More… ↓
